公开(公告)号：US12036268B2

公开(公告)日：2024-07-16

申请号：US15777456

申请日：2016-11-21

申请人： UNIVERSITAT AUTONOMA DE BARCELONA ,  FUNDACIÓ INSTITUCIÓ CATALÀ DE RECERCA I ESTUDIS AVANçATS

发明人： Miguel Chillon Rodriguez ,  Anna Masso Chacon ,  Assumpció Bosch Merino

IPC分类号： A61K38/47 ,  A61K9/00 ,  A61K45/06 ,  A61K48/00 ,  A61P25/28 ,  C07K16/40 ,  C12N9/24

CPC分类号： A61K38/47 ,  A61K9/0085 ,  A61K45/06 ,  A61P25/28 ,  C07K16/40 ,  C12N9/2402 ,  C12Y302/01031 ,  A61K48/00 ,  C12N2710/10043

摘要： The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention and/or treatment of cognitive and/or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.

公开(公告)号：US20240218019A1

公开(公告)日：2024-07-04

申请号：US18554180

申请日：2022-04-06

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Eduardo VILAR SANCHEZ ,  Kyle CHANG ,  Wenhui WU ,  Charles M. BOWEN ,  Krishna M. SINHA

IPC分类号： C07K7/08 ,  A61K9/00 ,  A61K38/00 ,  A61K39/00 ,  C07K14/74 ,  C12N5/0783 ,  C12N5/0784 ,  C12N15/86

CPC分类号： C07K7/08 ,  A61K9/0073 ,  A61K39/4611 ,  C07K14/70539 ,  C12N5/0636 ,  C12N5/0639 ,  C12N15/86 ,  A61K38/00 ,  C07K2319/00 ,  C12N2710/10043

摘要： The current disclosure provides methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to a peptide comprising at least 70% sequence identity to a peptide of one of SEQ ID NOS:1-776. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of one of SEQ ID NOS:1-776. Further aspects relate to pharmaceutical compositions comprising the peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.

公开(公告)号：US12012438B2

公开(公告)日：2024-06-18

申请号：US17346452

申请日：2021-06-14

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Jeffrey Schlom ,  Claudia M. Palena

IPC分类号： C07K14/47 ,  A61K9/127 ,  A61K38/17 ,  A61K38/19 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C12N15/86

CPC分类号： C07K14/4702 ,  A61K9/127 ,  A61K38/1709 ,  A61K38/193 ,  A61K39/0011 ,  A61K39/001152 ,  A61K39/00117 ,  A61K39/001182 ,  A61K45/06 ,  A61P35/00 ,  C12N15/86 ,  A61K2039/5256 ,  A61K2039/70 ,  C12N2710/10043 ,  Y02A50/30

摘要： The invention provides Brachyury deletion mutant polypeptides, nucleic acids encoding the polypeptides, non-yeast vectors comprising the nucleic acids, non-yeast cells, and methods of use.

公开(公告)号：US20240191255A1

公开(公告)日：2024-06-13

申请号：US18507263

申请日：2023-11-13

申请人： Gene Bridges GMBH

发明人： Adrian Francis Stewart ,  Jun Fu ,  Anja Ehrhardt ,  Eric Ehrke-Schulz ,  Wenli Zhang

IPC分类号： C12N15/86 ,  C12N7/00 ,  C12N9/22 ,  C12N15/11

CPC分类号： C12N15/86 ,  C12N7/00 ,  C12N9/22 ,  C12N15/11 ,  C12N2310/20 ,  C12N2710/10021 ,  C12N2710/10043 ,  C12N2800/80

摘要： The invention relates to adenoviral vectors, cells for use in generating adenoviral vectors, methods for generating adenoviral vectors, and therapeutic uses of adenoviral vectors in gene therapy, tumour therapy and as vaccines.

公开(公告)号：US20240189422A1

公开(公告)日：2024-06-13

申请号：US18529140

申请日：2023-12-05

申请人： MicroVAX, LLC

发明人： Albert B. Deisseroth ,  Nagy Habib

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K39/39558 ,  A61K39/0011 ,  A61K39/00117 ,  A61K39/39541 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/6031 ,  C12N2710/10043

摘要： A method and combination for treating a cancer patient by combining two distinct immuno-therapy solutions for administration to a patient within a common time period, comprising a checkpoint inhibitor antibody component such as a PD-1 or PD-L1 antibody administered by infusion, and a TAA/ecdCD40L vaccine component administered subcutaneously, wherein an initial antibody component administered is followed by at least several successive antibody boosts and an initial vaccine component administered is followed by at least several successive vaccine boosts, both the initial and boosts of each administered within at least said common time period, wherein the combined administration of said two distinct immuno-therapy solutions provides for an enhanced therapeutic effect, over that of the therapeutic effect of either of the two distinct immuno-therapy component solutions when administered alone as monotherapy.

公开(公告)号：US20240108752A1

公开(公告)日：2024-04-04

申请号：US18268392

申请日：2021-12-22

申请人： Ensoma, Inc.

发明人： Soumitra Roy ,  Ashvin Reddy Bashyam

IPC分类号： A61K48/00 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/17 ,  A61K38/46 ,  C12N15/86

CPC分类号： A61K48/0041 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/1774 ,  A61K38/465 ,  C12N15/86 ,  C12N2710/10022 ,  C12N2710/10043 ,  C12N2710/10071

摘要： The present disclosure includes adenoviral vectors characterized by efficient transduction of HSCs, e.g., for in vivo gene therapy. The present disclosure includes, among other things, Ad3, Ad7, Ad11, Ad14, Adpatentdocket@choate.com16, Ad21, Ad34, Ad37, and Ad50 vectors and genomes. Ad3, Ad7, Ad11, Ad14, Ad16, Ad21, Ad34, Ad37, and Ad50 vectors and genomes of the present disclosure can include therapeutic payloads.

公开(公告)号：US20240067985A1

公开(公告)日：2024-02-29

申请号：US18152699

申请日：2023-01-10

申请人： Gritstone bio, Inc.

发明人： Wade Blair ,  Brendan Bulik-Sullivan ,  Jennifer Busby ,  Adnan Derti ,  Leonid Gitlin ,  Karin Jooss ,  Ciaran Daniel Scallan ,  Roman Yelensky ,  Gijsbert Grotenbreg

IPC分类号： C12N15/86 ,  A61K35/761 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/74 ,  C07K16/28 ,  C12N7/00

CPC分类号： C12N15/86 ,  A61K35/761 ,  A61K39/0011 ,  A61K39/39541 ,  A61P35/00 ,  C07K14/70539 ,  C07K16/2818 ,  C12N7/00 ,  A61K2039/505 ,  A61K2039/5256 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/10071

摘要： Disclosed herein are chimpanzee adenoviral vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

公开(公告)号：US20240042061A1

公开(公告)日：2024-02-08

申请号：US18268752

申请日：2021-12-21

申请人： MULTIVIR INC.

发明人： Robert E. SOBOL ,  Kerstin B. MENANDER ,  Dora WIEDERHOLD ,  Sunil CHADA

IPC分类号： A61K48/00 ,  A61P11/00 ,  A61P35/00 ,  A61K45/06 ,  A61P31/20 ,  A61P31/14 ,  C12N15/86

CPC分类号： A61K48/0066 ,  A61P11/00 ,  A61P35/00 ,  A61K45/06 ,  A61P31/20 ,  A61P31/14 ,  C12N15/86 ,  C12N2710/10043 ,  C12N2710/10088

摘要： Provided herein are methods and compositions for suppressing or preventing an infection in a subject infected by a pathogen or decreasing organ or tumor tissue fibrosis that involve administering to the subject a composition that includes a therapeutically effective amount of a p53 therapy. Also disclosed are methods of suppressing tumor stroma by contacting the tumor stroma with the p53 therapy, wherein the p53 suppresses tumor stroma activities.

公开(公告)号：US11883487B2

公开(公告)日：2024-01-30

申请号：US17732127

申请日：2022-04-28

申请人： INPROTHER APS

发明人： Peter Holst ,  Christian Thirion ,  Lasse Neukirch

IPC分类号： A61K39/21 ,  A61K39/12 ,  A61K39/235 ,  A61K39/00 ,  C07K14/005 ,  A61P35/00 ,  C12N7/00 ,  C12N15/86 ,  A61P35/04

CPC分类号： A61K39/235 ,  A61K39/21 ,  A61P35/00 ,  A61P35/04 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/525 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/585 ,  C12N2710/10043 ,  C12N2740/10022 ,  C12N2740/10023 ,  C12N2740/10034 ,  C12N2740/10071

摘要： The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.

公开(公告)号：US20230405085A1

公开(公告)日：2023-12-21

申请号：US18313124

申请日：2023-05-05

申请人： INSTITUT PASTEUR ,  Centre National de la Recherche Scientifique (CNRS) ,  Sorbonne Universite ,  Universite Clermont Auvergne

发明人： Christine PETIT ,  Paul AVAN ,  Sedigheh DELMAGHANI ,  Jean DEFOURNY ,  Asadollah AGHAIE ,  Saaid SAFIEDDINE ,  Alice EMPTOZ

IPC分类号： A61K38/17 ,  A61K8/64 ,  A61K9/00 ,  A61Q19/02 ,  A61Q19/08 ,  A61K48/00 ,  A61K35/761 ,  C12N15/86 ,  C12N7/00 ,  C12N15/113

CPC分类号： A61K38/1709 ,  A61K8/64 ,  A61K9/0046 ,  A61Q19/02 ,  A61Q19/08 ,  A61K48/00 ,  A61K35/761 ,  A61K38/17 ,  A61K48/005 ,  C12N15/86 ,  A61K48/0075 ,  A61K9/0019 ,  C12N7/00 ,  C12N15/113 ,  A61K2800/91 ,  A01K2217/075 ,  A01K2267/0306 ,  C12N2750/14143 ,  A01K2227/105 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2710/10021 ,  C12N2710/10043

摘要： The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gas-dermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdennin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AA V2/8 vector expressing at least one USH1 gene product, preferably SANS.